The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology,” “Best Pharmaceutical Product,” “Best Public Sector Innovation” and “Best Health Equity Innovation”

— Winners to be Announced on 11

th

June at the Prix Galien UK Awards Ceremony in London

LONDON, May 12, 2026 /PRNewswire/ — The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2026 Prix Galien UK Award candidates for “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology,” “Best Pharmaceutical Product,” “Best Public Sector Innovation” and “Best Health Equity Innovation.” Winners will be selected by a committee of distinguished scientific leaders and announced during the Prix Galien UK Awards Ceremony, on 11th June at the Natural History Museum in London. To learn more and secure your ticket to the event, please visit our website here.

https://mma.prnewswire.com/media/2592709/The_Galien_Foundation_Logo.jpg

“Annually, the Prix Galien UK awards remind us that innovation in life sciences is not just about discovery, it’s about impact,” said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK Committee. “It is a privilege to return to this year’s Prix Galien UK Awards to recognise the latest cohort of innovators who embody the UK’s unwavering commitment to transforming scientific breakthroughs into better outcomes for patients, worldwide.”

The Prix Galien UK Awards Committee will be evaluating the innovation demonstrated throughout each product’s scientific development, clinical application, and utility. Further consideration is given to the insights it has advanced in biomedical science and the product’s tangible impact on human health.

“The Prix Galien stands as a global tribute to the power of human ingenuity in advancing health across the world,” said Bruno Cohen, Chairman of The Galien Foundation. “We look forward to continuing to honour those whose vision and dedication push the boundaries of medical progress as we approach the 2026 Prix Galien UK Awards.”

The 2026 Prix Galien UK Award Candidates are as follows:

Best Biotechnology Product (Candidates)

Company Product

—

Autolus Ltd
Aucatzyl

Kristal Biotech
Vyjuvek

Volition Nu.Q(R) Vet Cancer
Test

Best Digital Health Solution (Candidates)

Company Product

—

August International Limited AI-Powered Real-time Telehealth
Scheme

Evaxion AI-Immunology(TM) platform

Evinova
Unified Trial Solution

Gulsine ltd.
A2P2 Platform

HARLEYDOC
HARLEYDOC APP

House of Possibility Limited
Rapid Tapping(R)
(TRADING AS RAPID TAPPING)

Otsuka Pharmaceuticals (UK) Ltd
Rejoyn

Perspectum
CoverScan

SökerData
SökerScan

Viscera Technologies Ltd
Quantico

Best Medical Technology (Candidates)

Company Product

—

MiniMed MiniMed Go Smart MDI
system

Novocure UK Limited
Optune Gio

Nyxoah SA
Genio

Smith & Nephew Medical Ltd.
RENASYS EDGE

THERMOTRAUMAPORT LTD THERMOTRAUMAPORT

U-test diagnostics
U-test @ Home

Best Pharmaceutical Product (Candidates)

Company Product

—

AbbVie UK
Elahere(R)

Aventis Pharma (SANOFI)
TZIELD

Blueprint Medicines, a Sanofi company

Gilead Sciences Ltd
Sunlenca/Yeytuo

Incyte Biosciences UK Ltd Opzelura(R) (ruxolitinib) 15
mg/g cream

Novartis Pharmaceuticals UK
Iptacopan▼

PhytoQuest Limited
Q-actin(R)

Servier Laboratories Ltd
Voranigo▼

Shionogi
Fetcroja

ViiV Healthcare
Apretude

Best Public Sector Innovation (Candidates)

Company

Product

—

BioDundee
BioDundee’s Life Sciences and Healthcare Innovation Ecosystem

University College London Centre for Digital Digital platform for vector-borne diseases (VBD) surveillance and early warning
in Brazil and Madeira
Public Health in Emergencies (UCL dPHE)

University of Glasgow Intensive low-calorie weight management programme to induce type 2 diabetes
remission

University of Liverpool Liverpool’s COVID-19 Trio: ISARIC (clinical characterisation), SMART (testing)
and AGILE (trials)

University of Liverpool and Liverpool University
LDIR Tech
Hospitals NHS Foundation Trust

Well Cool Clothing Ltd
Well Cool Patient Wear

Best Health Equity Innovation (Candidates)

Company

Product

—

Agios Pharmaceuticals, Inc. Clinical Trials Designed with Patients, for Patients: RISE UP Sickle Cell
Disease Clinical Program

Eli Lilly as the Sponsor in collaboration with An open-label, pragmatic clinical trial in a UK real world setting in people
living with obesity
North West e-Health, Health Innovation
Manchester and the University of Manchester

HARLEY of LONDON Harley Wellness Dollar Empowering Community Health, Wellness and Lifestyle

National Institute for Health and Care NICE technology appraisal guidance (TA1044) for exagamglogene autotemcel
(exa-cel) for
Excellence (NICE) treating severe sickle cell disease in people 12 years and over. TA1044

Nuffield Department of Primary Care Centre for Research Equity through pharmacy, communities and healthcare
Health Sciences University of Oxford

ProFactor Pharma
Affordable recombinant Factor VIII

Quercis Pharma AG
Kinisoquin(TM)

Sisters of Support CIC
Sisters of Support

The Drug Discovery Unit, University of Dundee
Drug Discovery for Neglected Infectious Diseases

University of Glasgow Enabling equitable access to lifesaving rabies post-exposure prophylaxis

The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 62 products since its inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 12 experts in the field, and includes a number of the UK’s leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.

During the ceremony, the 2026 Prix Galien UK Lifetime Achievement Award will be bestowed upon Dame Kate Bingham, Former Chair of the UK Government’s Vaccine Taskforce. The keynote address will be delivered by Dr John-Arne Røttingen, MD, PhD, CEO, Wellcome; Committee Member, Prix Galien Bridges.

Prix Galien UK Awards Committee 2026

Professor Sir Munir PIRMOHAMEDDavid Weatherall Chair of Medicine, University of Liverpool, NHS Chair of PharmacogeneticsCommittee Chair

Professor Jane ADAMHonorary Professor, University of Exeter, Consultant Radiologist, St George’s Hospital London and former Chair Technology appraisal committee, NICE

Professor Bruce CAMPBELLPast Chair NICE Interventional Procedures and Medical Technologies Advisory Committees; Honorary Vascular Consultant and Professor, Exeter

Alison CAVE, PhDChief Safety Officer, Medicines and Healthcare products Regulatory Agency (MHRA)

Professor Jesse DAWSONProfessor of Stroke Medicine at School of Cardiovascular and Metabolic Health in the College of Medical, Veterinary and Life Sciences at the University of Glasgow; Consultant Physician in the Queen Elizabeth University Hospital, Glasgow

Doctor Stephanie KUKUChief Knowledge Officer – Conceivable Life Sciences, Senior Consultant – Hardian Health, Board Trustee – The Kings Fund, Honorary Senior Research Fellow, UCL

Professor Sudhesh KUMAR, OBEVice President (Health), University of Warwick and President of Association of Innovation, Research and Technology Organisations, UK (AIRTO)

Professor Andrew MORRIS, CBEDirector, Health Data Research UK & Professor of Medicine and Vice Principal Data Science, University of Edinburgh

Professor Sharon PEACOCK, CBEMaster of Churchill College Cambridge

Professor Duncan RICHARDSProfessor of Clinical Therapeutics, University of Oxford

Doctor Lauren WALKERProfessor of Clinical Pharmacology & Therapeutics, University of Liverpool

Professor Dame Moira WHYTESir John Crofton Professor of Respiratory Medicine, University of Edinburgh

About The Galien Foundation The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates in 16 countries across Africa, Europe, the United States and the UK. Expansion is currently underway in South Korea, Japan, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognises up to three individuals for specific discoveries, the Prix Galien honours the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

See the UK Hall of Fame: https://infogram.com/prix-galien-uk-since-1990-1hnp27e0qqyzn4g.

Follow the Foundation on social media:https://www.facebook.com/GalienFoundation/ https://twitter.com/GalienFdnhttps://www.linkedin.com/company/the-galien-foundation/

Media Contact (UK):Julian Tyndale-BiscoeFinn [email protected]+44 20 3217 7060

Media Contact (Global):Kara BradleyFinn [email protected]

Logo – https://mma.prnewswire.com/media/2592709/The_Galien_Foundation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-galien-foundation-announces-2026-prix-galien-uk-award-candidates-for-best-biotechnology-product-best-digital-health-solution-best-medical-technology-best-pharmaceutical-product-best-public-sector-innovation-and–302768995.html